Scholarlink

<p>There is currently insufficient evidence regarding the safety and effectiveness of influenza vaccination in B-cell-mediated autoimmune diseases such as pemphigus. This study aims to assess the effects of the influenza vaccine on patients with pemphigus. Sixty patients were randomly divided into vaccination and control groups. Patients were followed for 12 months while flu symptoms (including fever, cough, and rhinitis), flu PCR results, Anti-desmoglein 1, 3 antibodies, and Pemphigus Disease Area Index scores were evaluated at baseline and 6-month intervals. We observed no significant difference in the cumulative and daily doses of prednisolone between the two groups (Ps = 0.12, 0.47, respectively). Similarly, the incidence of flu cases in the vaccinated group (13.79%) did not differ significantly from that in the control group (19.05%, <i>P</i> = 0.71). The recurrence rate of pemphigus was also statistically similar between vaccinated (62.07%) and unvaccinated patients (52.38%, <i>P</i> = 0.69). The findings of this study do not support a significant association between vaccination and relapse and could help mitigate concerns about influenza vaccination triggering pemphigus recurrence.</p><p><i>Trial registration: </i>The study was registered in the IranianRegistry of Clinical Trials (IRCT registration number:IRCT20191022045185N1) (<a href="https://irct.behdasht.gov.ir/trial/43194">https://irct.behdasht.gov.ir/trial/43194</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy and safety of influenza vaccine in pemphigus in the COVID-19 era: A randomized trial

  • 期刊论文

  • 发表日期：

    2026年3月10日

查看全文
  • Maryam Hadi,
  • Ahmad Vafaeian,
  • Maryam Daneshpazhooh,
  • Soheil Tavakolpour,
  • Tahereh Soori,
  • Ali Salehi Farid,
  • Zeinab Farimani,
  • Hamidreza Mahmoudi

摘要

There is currently insufficient evidence regarding the safety and effectiveness of influenza vaccination in B-cell-mediated autoimmune diseases such as pemphigus. This study aims to assess the effects of the influenza vaccine on patients with pemphigus. Sixty patients were randomly divided into vaccination and control groups. Patients were followed for 12 months while flu symptoms (including fever, cough, and rhinitis), flu PCR results, Anti-desmoglein 1, 3 antibodies, and Pemphigus Disease Area Index scores were evaluated at baseline and 6-month intervals. We observed no significant difference in the cumulative and daily doses of prednisolone between the two groups (Ps = 0.12, 0.47, respectively). Similarly, the incidence of flu cases in the vaccinated group (13.79%) did not differ significantly from that in the control group (19.05%, P = 0.71). The recurrence rate of pemphigus was also statistically similar between vaccinated (62.07%) and unvaccinated patients (52.38%, P = 0.69). The findings of this study do not support a significant association between vaccination and relapse and could help mitigate concerns about influenza vaccination triggering pemphigus recurrence.

Trial registration: The study was registered in the IranianRegistry of Clinical Trials (IRCT registration number:IRCT20191022045185N1) (https://irct.behdasht.gov.ir/trial/43194).